Boston-based Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell-based cellular therapies, is $62 million richer. 7 February 2023
Genetic medicines company 4D Molecular Therapeutics has announced that its Fabry disease gene therapy program has been placed on clinical hold by the US Food an 6 February 2023
Positive results from the Phase III CARTITUDE-4 study show the novel BCMA-directed T-cell therapy Carvykti (ciltacabtagene autoleucel) performed well in the tre 30 January 2023
The European Medicines Agency is to review a regulatory submission from Swiss gene-editing specialist CRISPR Therapeutics and partner Vertex Pharmaceutical. 25 January 2023
Fatal cases of acute liver failure reported in patients treated with Zolgensma (onasemnogene abeparvovec) were raised this week at the European Medicines Agency 13 January 2023
Boston-based Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, has announ 9 January 2023
One of the pioneers of mRNA technologies, BioNTec, is investing the proceeds of its work during the pandemic on its original focus - cancer vaccines. 6 January 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.